Search

Amphastar Pharmaceuticals Inc

Открыт

СекторЗдравоохранение

20.93 4.08

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

19.82

Макс.

21.03

Ключевые показатели

By Trading Economics

Доход

24M

30M

Продажи

13M

184M

P/E

Средняя по отрасли

12.309

57.002

Прибыль на акцию

0.8

Рентабельность продаж

16.502

Сотрудники

1,976

EBITDA

12M

45M

Рекомендации

By TipRanks

Рекомендации

Нейтрально

Прогноз на 12 месяцев

+7.38% upside

Дивиденды

By Acuity

Следующий отчет о доходах

5 нояб. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

18M

864M

Предыдущая цена открытия

16.85

Предыдущая цена закрытия

20.93

Новостные настроения

By Acuity

84%

16%

319 / 340 Рейтинг в Healthcare

Amphastar Pharmaceuticals Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

12 авг. 2026 г., 20:06 UTC

Amphastar Pharmaceuticals Inc shares are lower in Wednesday's session, continuing a decline from Tuesday's close amid fluctuating U.S. Treasury yields and inflation data.

11 авг. 2026 г., 19:56 UTC

News

Amphastar Pharmaceuticals reported Q2 revenue of $183.9 million, exceeding expectations. Shares are modestly higher amid strong demand for key products and new launches.

10 авг. 2026 г., 19:36 UTC

News

Amphastar Pharmaceuticals reported Q2 earnings of $0.70 per share on $183.9 million in revenue, but shares are trading lower today amid a slight net income decline.

7 авг. 2026 г., 19:51 UTC

News

Amphastar Pharmaceuticals reported Q2 EPS of $0.91, exceeding estimates. Revenue also surpassed expectations, contributing to a positive market response and higher shares.

6 авг. 2026 г., 23:02 UTC

News

Amphastar Pharmaceuticals reported second-quarter sales of $183.9 million, exceeding expectations. Shares are trading higher in after-market hours following the strong results.

4 авг. 2026 г., 19:51 UTC

Amphastar Pharmaceuticals is trading lower today, breaking a trend of higher daily closes. No specific news was identified to explain the decline.

3 авг. 2026 г., 19:46 UTC

Amphastar Pharmaceuticals Inc is trading higher, reaching a session high amid positive market conditions and falling oil prices influencing investor sentiment.

31 июл. 2026 г., 19:36 UTC

Amphastar Pharmaceuticals is declining today, continuing a downward trend since Thursday. The stock reached a session low earlier this morning amid broader market volatility.

30 июл. 2026 г., 19:28 UTC

Amphastar Pharmaceuticals Inc. shares are lower amid significant downward pressure in the Pharmaceuticals sub-sector, reflecting broader sector weakness during Thursday's session.

29 июл. 2026 г., 20:41 UTC

Amphastar Pharmaceuticals shares are lower in after-market trading, continuing a decline amid rising crude oil prices and geopolitical tensions in the Middle East.

28 июл. 2026 г., 20:02 UTC

Amphastar Pharmaceuticals shares are higher today, diverging from a broader market decline amid a sell-off in technology stocks across Asian markets.

24 июл. 2026 г., 19:06 UTC

Amphastar Pharmaceuticals is trading higher, supported by a pullback in crude oil prices, which has eased some inflationary pressures affecting investor sentiment.

22 июл. 2026 г., 20:06 UTC

Amphastar Pharmaceuticals Inc shares are lower today, continuing a four-session decline amid market uncertainty ahead of the Federal Reserve meeting on July 29.

21 июл. 2026 г., 19:46 UTC

Amphastar Pharmaceuticals Inc is trading lower, continuing a three-session decline. No specific news was identified to explain the stock's performance.

20 июл. 2026 г., 19:56 UTC

Amphastar Pharmaceuticals is gaining modestly during Monday's session amid mixed market conditions and geopolitical tensions affecting oil prices and inflation concerns.

Сравнение c конкурентами

Изменение цены

Amphastar Pharmaceuticals Inc Прогноз

Целевая цена

By TipRanks

7.38% рост

Прогноз на 12 месяцев

Средняя 21.67 USD  7.38%

Максимум 30 USD

Минимум 20 USD

Основано на мнении 6 аналитиков Wall Street, спрогнозировавших целевые цены для Amphastar Pharmaceuticals Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Нейтрально

6 ratings

0

Покупка

5

Удержание

1

Продажа

Настроения

By Acuity

319 / 340Рейтинг в Здравоохранение

Новостные настроения

Сильные свидетельства нисходящего тренда

Волатильность

Ниже среднего

Объем новостей (RCV)

Выше среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Amphastar Pharmaceuticals Inc

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
help-icon Live chat